Company intelligence / Profile preview

Mi-Helper

Annapolis, Maryland, United Statesmihelper.com ↗

Ownership: Private
Development stage: Phase 1

Overview

Mi‑Helper is developing a patented, non-invasive neuromodulation device for at-home migraine relief. The device delivers conditioned air and nebulized mist to the nasal mucosa, targeting nerve pathways involved in migraine pain. Early clinical studies suggest promise for rapid symptom relief, but the product remains investigational and is currently undergoing decentralized clinical trials in partnership with ObvioHealth[2][3]. Prior studies have been conducted at institutions such as Mayo Clinic, Michigan State University, and Atrium Health[8].

Therapeutic areas: Neurology
Modalities: DeviceNon-pharmacological therapyNeuromodulation device therapy
Industry: Therapeutic Medical Devices

Partnerships

ObvioHealth (decentralized clinical trial partner)[2]

Beyond the preview

Go deeper on Mi-Helper.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Mi-Helper.

Explore the full profile